Orion Portfolio Solutions’s Heron Therapeutics HRTX Stock Holding History

Orion Portfolio Solutions’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16	Closed	–	–	2069
2019 Q4	$0	Buy	+16	New	+$354	﹤0.01%	1860

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Orion Portfolio Solutions's HRTX Position: Q1 2020 in Review

Orion Portfolio Solutions sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 16 shares.

Orion Portfolio Solutions first reported a position in HRTX in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Orion Portfolio Solutions reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Orion Portfolio Solutions sold 16 Heron Therapeutics shares in Q1 2020.
Orion Portfolio Solutions first reported a position in Heron Therapeutics in Q4 2019 and held it in 1 quarter.
Orion Portfolio Solutions's Heron Therapeutics position peaked at $0 in Q4 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Orion Portfolio Solutions's 13F filing for Q1 2020, filed 15 May 2020.